Cell deposition and staining apparatuses and methods are disclosed herein. In particular, the deposition and staining apparatuses disclosed herein provide low-volume, automated bench top systems for depositing and staining cellular samples on a cytological slide. An example deposition and staining apparatus includes a housing having an access door; a substrate processing holder located within the housing configured to hold one or more substrates and/or one or more substrate cartridges, wherein the substrate processing holder is accessible when the access door is in an open configuration; at least one opening located at least partially above at least a portion of the substrate processing holder; a spray nozzle configured to dispense a gaseous substance into the substrate processing area; a user interface configured receive an input from a user, and in response to receiving the input, cause execution of a pre-programmed protocol; and a waste and/or reagent holder element.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 1/28 - Préparation d'échantillons pour l'analyse
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
2.
METHODS FOR TREATING HIGH RISK MYELODYSPLASTIC SYNDROMES
The present invention provides methods of using an inhibitor of the IL-6 signaling pathway to inhibit disease progression in a subject with a high-risk myelodysplastic syndrome (MDS) or treat low blast count acute myeloid leukemia (AML). Methods for identifying therapeutics for preventing MDS to AML progression are also provided.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
3.
LIPID NANOPARTICLES AND METHODS OF USING THE SAME FOR TREATING CELL PROLIFERATIVE DISEASES AND DISORDERS
Provided herein are bi-specific lipid nanoparticles (B-LNPs), pharmaceutical compositions comprising the same, and methods of using the same to treat cell proliferative diseases or disorders, e.g., glioblastoma multiforme.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
One aspect of this invention relates to a method for producing a carbide-free bainite and retained austenite steel. The method includes providing an iron alloy containing a composition designed according to property objectives of the carbide-free bainite and retained austenite steel; heat-treating the alloy to a temperature above a temperature at which a transformation from ferrite into austenite is finished; succeedingly quenching the heat-treated alloy to a bainite region at a temperature between a first temperature at which a martensitic transformation starts in the alloy and a second temperature at which a coupled diffusional/displacive bainitic transformation starts the alloy; and optimally cooling the quenched alloy to form to form the carbide-free bainite and retained austenite steel that meets the property objectives, with a cooling ratio precisely controlled so that the temperature of the alloy continues to be slightly above the first temperature which keeps decreasing during the optimally cooling step.
C21D 6/00 - Traitement thermique des alliages ferreux
C21D 8/02 - Modification des propriétés physiques par déformation en combinaison avec, ou suivie par, un traitement thermique pendant la fabrication de produits plats ou de bandes
Disclosed herein are compositions and methods that can achieve photoreduction of CO2 to CO in pure water at pH 6-7 with excellent performance parameters. In embodiments, the compositions and methods use CuInS2 colloidal quantum dots (QDs) as photosensitizers, and a Co-porphyrin catalyst.
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage utilisant des radiations électromagnétiques
B01J 31/18 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination contenant de l'azote, du phosphore, de l'arsenic ou de l'antimoine
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C09K 11/62 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du gallium, de l'indium ou du thalium
6.
MIXED-KERNEL HETEROJUNCTION TRANSISTORS, FABRICATING METHODS, AND APPLICATIONS OF THE SAME
This invention in one aspect relates to a mixed-kernel heterojunction transistor, comprising a monolayer film formed of an atomically thin material, and a network of carbon nanotubes (CNTs) vertically stacked over the monolayer film to define an overlap region of the CNT network with the monolayer film, and non-overlap regions of the monolayer film and the CNT network, wherein the overlap region is a mixed-kernel van der Waals heterojunction.
H10K 19/20 - Dispositifs intégrés, ou ensembles de plusieurs dispositifs, comprenant au moins un élément organique spécialement adapté au redressement, à l'amplification, à l'oscillation ou à la commutation couvert par le groupe . comprenant des composants ayant une région active qui comprend un semi-conducteur inorganique
A61B 5/308 - Circuits d’entrée à cet effet spécialement adaptés à des utilisations particulières pour l’électrocardiographie [ECG]
A61B 5/332 - Dispositifs portables spécialement adaptés à cet effet
A61B 5/339 - Affichages spécialement adaptés à cet effet
A61B 5/349 - Détection de paramètres spécifiques du cycle de l'électrocardiogramme
H10K 19/10 - Dispositifs intégrés, ou ensembles de plusieurs dispositifs, comprenant au moins un élément organique spécialement adapté au redressement, à l'amplification, à l'oscillation ou à la commutation couvert par le groupe . comprenant des transistors à effet de champ
H10K 85/20 - Composés de carbone, p. ex. nanotubes de carbone ou fullerènes
7.
NANOCOMPOSITES, NANOCOMPOSITE SENSORS AND RELATED METHODS
Methods for making nanocomposites are provided. In an embodiment, such a method comprises combining a first type of nanostructure with a bulk material in water or an aqueous solution, the first type of nanostructure functionalized with a functional group capable of undergoing van der Waals interactions with the bulk material, whereby the first type of nanostructure induces exfoliation of the bulk material to provide a second, different type of nanostructure while inducing association between the first and second types of nanostructures to form the nanocomposite.
C12N 9/04 - Oxydoréductases (1.), p.ex. luciférase agissant sur des groupes CHOH comme donneurs, p.ex. oxydase de glucose, déshydrogénase lactique (1.1)
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
8.
INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTS
Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.
Provided herein are monoclonal antibodies (mAbs) that bind to human Cluster of Differentiation 73 (CD73). In particular, anti-CD73 mAbs are provided that bind to and inhibit the activity of human CD73.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
10.
RIBOSOME-MEDIATED POLYMERIZATION OF NOVEL CHEMISTRIES
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Jewett, Michael Christopher
Lee, Joongoo
Anslyn, Eric V.
Coronado, Jaime
Lim, Jongdoo
Abrégé
Disclosed are methods, systems, components, and compositions for synthesis of sequence defined polymers. The methods, systems, components, and compositions may be utilized for incorporating novel substrates that include non-standard amino acid monomers and non-amino acid monomers into sequence defined polymers. As disclosed herein, the novel substrates may be utilized for acylation of tRNA via flexizyme catalyzed reactions. The tRNAs thus acylated with the novel substrates may be utilized in synthesis platforms for incorporating the novel substrates into a sequence defined polymer.
Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
12.
METHODS FOR PREPARING PROTEIN-CONJUGATED NANOCARRIERS
Provided herein are methods for functionalizing nanoparticles with functional proteins, and methods of using the functionalized nanoparticles. Compositions for preparing the functionalized nanoparticles are also described herein.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
13.
METHODS FOR ASSEMBLING PROTEIN-CONJUGATED NANOCARRIER VACCINES
Provided herein are vaccine compositions for preparing nanocarriers comprising NiVF and NiVG virus proteins. Methods for preparing and using the nanocarriers for eliciting neutralizing antibodies or treating a Nipah virus infection are also described herein.
One aspect of the invention relates to a method for fabricating a memtransistor comprising growing a polycrystalline monolayer film on a substrate, wherein the polycrystalline monolayer film contains grains defining a plurality of grain boundaries thereof; and forming an electrode array on the grown polycrystalline monolayer film, wherein the electrode array has a plurality of electrodes electrically coupled with the polycrystalline monolayer film such that each pair of electrodes defines a channel in the polycrystalline monolayer film therebetween.
H10N 70/20 - Dispositifs de commutation multistables, p.ex. memristors
G11C 13/00 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou
H10B 63/00 - Dispositifs de mémoire par changement de résistance, p.ex. dispositifs RAM résistifs [ReRAM]
H10N 70/00 - Dispositifs à l’état solide sans barrière de potentiel ni de surface, spécialement adaptés au redressement, à l'amplification, à la production d'oscillations ou à la commutation
15.
RATIONAL DESIGN, OPTIMIZATION, AND BIOLOGICAL EVALUATION OF NOVEL MEK4 INHIBITORS AGAINST PANCREATIC ADENOCARCINOMA
Disclosed are indazole compounds and derivatives thereof for use as modulators of the activity of mitogen-activated protein kinase 4 (MEK4). The disclosed compounds include 3-arylindazoles and 3-amino-indazoles which may be formulated in pharmaceutical composition for treating cell proliferative diseases and disorders associated with MEK4 activity, including cancer.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
16.
MICROCHIPS FOR USE IN ELECTRON MICROSCOPES AND RELATED METHODS
Method for fabricating a microchip are provided which may comprise forming a dopant mask layer on a front side surface of a silicon substrate having the front side surface and an opposing back side surface; removing a portion of the dopant mask layer according to a pattern to form a first exposed silicon region in the silicon substrate and a first unexposed silicon region in the silicon substrate; doping the first exposed silicon region in the silicon substrate with a p-type dopant to form a first p-type doped silicon region in the silicon substrate; forming a silicon nitride layer on the front side surface of the silicon substrate comprising the first p-type doped silicon region and the first unexposed silicon region; and forming an opening in the silicon substrate from the opposing back side surface of the silicon substrate to provide a microchip comprising the silicon substrate having the opening, a first silicon nitride window positioned within the opening, and a support structure mounted to the first silicon nitride window, the support structure comprising the first p-type doped silicon region. The fabricated microchips and methods of using the microchips are also provided.
A physics-based network model is trained to learn weights such as trapping, detrapping, and/or transport of holes and/or electrons, as well as voltage distribution on a voxel-by-voxel basis throughout a solid-state detector model. The physics-based network may be used to estimate material property variation throughout the voxels. To reduce the number of experimental setups and information needed to train the models, the models may be trained using more easily acquired ground truth. Just the electrode signals or just the free charge data is used to train the model to characterize the solid-state detector. With this reduced data, the detector may be characterized using equivalency, such as combining multiple trapping centers to an equivalent trapping center. Regularization may be used in the loss calculation, such as where just the electrode signals are used, to deal with the reduced data available as ground truth.
The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a subject, and methods of improving use of immune checkpoint modulators in brain cancers. Also disclosed herein are compositions and methods for treating a brain tumor.
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
The present disclosure provides fusion proteins comprises fusion proteins comprising the signal sequence of PduB or PduM and a heterologous protein, as well as constructs for expressing the fusion proteins, and methods of their use. The fusion proteins are designed to deliver the heterologous proteins to bacterial microcompartments and modify the 1,2-propanediol metabolic pathway.
A wearable device includes an elastically compliant body having a side for attaching to skin of a patient, a plurality of accelerometers for receiving acoustic wave data from acoustic waves transmitted by a transducer, a short-range radio transmitter for transmitting the acoustic wave data to a computing device, a processor for receiving the acoustic wave data from the plurality of accelerometers and providing the acoustic wave data to the short-range radio transmitter, and a battery for providing power to the processor, the plurality of accelerometers, and the short-range radio transmitter. A distance between each accelerometer of the plurality of accelerometers is predetermined. The processor, the plurality of accelerometers, the short-range radio transmitter, and the battery are embedded within the elastically compliant body.
Disclosed are substituted pyrrolo[2,3-d]pyrimidine compounds. The disclosed compounds are shown to be useful in inhibiting the growth of cancer cell lines and treating cancer and cell proliferative disorders.
Provided herein are systems comprising magnetically-couplable stents and catheters that allow for locating and retrieving the stents from within a subject. In particular, the systems herein comprise a magnetically-couplable stent and catheter, a guide wire capable of being advanced through the lumens of the stent and catheter, and a retrieval element (e.g., balloon) capable of being advanced through the lumens of the stent and catheter and stably gripping the stent. This method aims to maintain wire access across the pathology that the stent is crossing.
23.
COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS
The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NF AT, NF-KB and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.
A system for measuring a radiant exposure of electromagnetic radiation comprises an accumulation detection module (ADM) comprising a detector and configured to continuously monitor an electromagnetic radiation received by the detector; and an adaptive circuit configured to periodically interrogate the ADM; adjust a frequency of interrogation of the ADM based on an intensity of the electromagnetic radiation received by the detector; and autonomously transmit information related to an amount of the electromagnetic radiation received by the detector to a remote device.
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1) or (FX2). The polymer of formula (FX1) or (FX2) in some aspects inhibits the protein-protein interaction between VCP and mutant-type Huntingtin protein.
C08G 61/08 - Composés macromoléculaires contenant uniquement des atomes de carbone dans la chaîne principale de la molécule, p.ex. polyxylylènes uniquement des atomes de carbone aliphatiques préparés par ouverture du cycle des composés carbocycliques des composés carbocycliques contenant une ou plusieurs doubles liaisons carbone-carbone dans le cycle
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present disclosure is generally directed to a method of monitoring and treating a disorder and a system for monitoring and treating a disorder. The method includes monitoring a subject, determining a time period that the risk of an adverse event, such as a risk of stroke provoked by a cardiac arrhythmia (such as atrial fibrillation AFib), is elevated, and administering a medical treatment or notifying a patient to begin a treatment, such as starting to take daily a direct acting oral anticoagulant DOAC. The system includes a device to monitor the patient that is communicatively coupled to a server. The server receives monitoring data from the device and transmits the data to a storage database. In response to the device detecting data indicative of a meeting or exceeding a predetermined threshold, the server sends a notification to the patient via the device.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
Provided herein are endoscopes with a transparent balloon mounted thereon that find use in angioscopy and cardioscopy. In particular, an endoscope-mounted balloon with a transparent lining that can be inflated with transparent liquid and apposed to the wall of a blood vessel or the heart allows visualization of the adjacent structures through the balloon.
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
28.
LITHIUM-CONTAINING THIOSTANNATE SPINELS FOR THERMAL NEUTRON AND ALPHA-PARTICLE DETECTION
Lithium-containing thiostannate spinel compounds having the formula Li2M1+xSn3−xS8, where x is 0 or 1 and M is Mg, Fe, Mn, Ni, Ga, In, or a combination thereof; or the formula Li1.66CuSn3.33S8 are provided. Methods and devices for detecting incident neutrons and alpha-particles using the compounds are also provided. For thermal neutron detection applications, the compounds can be enriched with lithium-6 isotope (6Li) to enhance their neutron detecting capabilities.
Embodiments of a Stochastic memristive array (SMA) device based on arrays of voltage-controlled magnetic tunnel junctions (MTJs) are disclosed. The SMA device is based on an array of stochastic (low energy barrier) magnetic tunnel junctions that are connected in parallel which simultaneously exhibits features that include (i) stochasticity and (ii) memristive behavior. The energy barrier of the MJTs may be tuned by an applied voltage (electric field). SMA devices may find applications in emerging computing concepts such as probabilistic computing and memcomputing, among others, providing a pathway towards intelligent hybrid CMOS-spintronic systems.
G11C 11/16 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliers; Eléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments dans lesquels l'effet d'emmagasinage est basé sur l'effet de spin
Disclosed herein are components, kits, platforms, and systems for novel, bacterial-based, cell-free glycosylation for incorporating non-canonical sugars and constructing azido-sialoglycoprotein structures.
Compositions for forming porous materials and three-dimensional objects, including fibers, films and coatings made from the materials are provided. Also provided are methods for forming the porous objects from the compositions. The compositions include a solvent, a polymer binder that is soluble in the solvent, and solid particles that are insoluble in the solvent. The solid particles include water-soluble salt particles that can be selectively dissolved from objects made from the compositions to render the resulting structures porous.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/44 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
C08J 9/26 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolaires; Leur post-traitement par élimination d'une phase solide d'un objet ou d'une composition macromoléculaire, p.ex. par lessivage
C08L 67/04 - Polyesters dérivés des acides hydroxycarboxyliques, p.ex. lactones
32.
BIOPANNING METHODS FOR IDENTIFYING PEPTIDES TARGETING GLIAL PHENOTYPES IN RAMIFIED, PRIMED, AND ACTIVATED BRAIN MICROGLIA AND ASTROCYTES
Provided herein are biopanning methods for identifying peptides that bind to one or more glial cell subtypes, and peptides identified using the methods described herein. In some embodiments, provided herein are biopanning methods for identifying peptides that bind to glial cell subtypes including surveying glial cells, active glial cells, and/or primed glial cells.
Disclosed herein are compounds, compositions, and methods for inhibiting HECT E3 ubiquitin ligases. In some embodiments, the compounds are formulated as a pharmaceutical composition and administered to a subject in need thereof. In some embodiments, the subject in need thereof is diagnosed with a neurological disease or a cancer characterized by increased or ectopic HECT E3 ligase activity.
Convolution-Hierarchical Deep-learning Neural Network (C-HiDeNN) is a customized neural network that can solve and train partial differential equations for various Computational Science and Engineering (CS&E) problems including but not limited to linear/nonlinear solid mechanics problems, damage/fracture problems, thermal and fluid problems, multiphysics and multiscale problems, and many more. Compared to classical numerical methods such as Finite Element Analysis (FEA), C-HiDeNN is much more accurate and faster due to the architecture of hierarchical deep neural networks (DNNs) with convolution layers. The training of C-HiDeNN renders versatile local and global mesh adaptivity which further improves the efficiency of the numerical method.
A system to perform reversible transvenous electroporation includes an electroporation generator and a controller operably coupled to the electroporation generator. The controller is configured to instruct the electroporation generator to generate a voltage signal to perform electroporation, where the voltage signal has a predetermined range of voltages and a predetermined range of pulse widths to ensure that the electroporation is reversible, and where the voltage signal is biphasic or monophasic. The controller also delivers the voltage signal to a catheter to perform the electroporation, where the catheter includes one or more electrodes through which the voltage signal is delivered.
A61N 1/02 - SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE ÉLECTROTHÉRAPIE; MAGNÉTOTHÉRAPIE; THÉRAPIE PAR RADIATIONS; THÉRAPIE PAR ULTRASONS Électrothérapie; Circuits à cet effet - Parties constitutives
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
36.
AQUEOUS FORMULATIONS OF CYTOTOXIC TAXANES WITH CYCLODEXTRIN
Provided in the present disclosure are complexes and solutions demonstrating improved aqueous solubility of derivatized cytotoxic taxane drug moieties. In some other aspects, the disclosure provides methods of using such complexes and solutions for the treatment of cancer. In some further aspects, the disclosure provides combination therapies that may be suitable when used in combination with the use of the complexes disclosed herein.
C07D 305/14 - Composés hétérocycliques contenant des cycles à quatre chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Disclosed herein are low dielectric constant (low-k) two-dimensional covalent organic framework materials that have a dielectric constant k less than 2.4, optionally less than 1.9, and are comprised of regularly porous, covalently linked, layer structures.
Methods of forming κ-phase gallium oxide materials are provided, including highly conductive and highly phase stable such materials. In embodiments, the method comprises exposing a surface of a substrate positioned in a metalorganic chemical vapor deposition (MOCVD) reactor to a gallium (Ga) precursor vapor, an indium (In) precursor vapor, an oxygen (O) precursor vapor, and a silicon (Si) precursor vapor, under conditions to form a κ-phase gallium oxide material on the surface of the substrate. The κ-phase gallium oxide material comprises Ga, O, Si, and further comprises no more than 0.1 weight % In.
H01L 29/24 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des matériaux semi-conducteurs inorganiques non couverts par les groupes , , ou
39.
SURFACE COATING PPSU NANOPARTICLES FOR THERAPEUTIC MODULATION OF MAST CELLS
The present disclosure provides methods of adsorbing proteins to the surface of a nanoparticle. Particularly, methods for adsorbing anti-Siglec-6 and anti-FcεRI antibodies to PPSU nanoparticles, are described. The disclosure further provides compositions comprising the nanoparticles are methods of their use to prevent mast cell secretion and anaphylaxis.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
40.
CONVOLUTION HIDENN-TENSOR DECOMPOSITION FOR MANUFACTURING SIMULATION, PERFORMANCE PREDICTION, AND TOPOLOGY OPTIMIZATION OF MULTISCALE MATERIAL SYSTEMS
Convolution-Hierarchical Deep-learning Neural Network – Tensor decomposition (C-HiDeNN-TD) has four features: (1) Tensor decomposition breaking down the whole design into small tractable problems; (2) Convolution built-in filter to increase accuracy without adding extra DoFs; (3) Convolution built-in filter can avoid checkerboard pattern; (4) Design can have arbitrary smoothness without adding extra DoFs.
Methods of growing large, free-standing single crystals of (FAxCs1-x)PbBr3 perovskites, where 0≤x<1, in solution using tertiary or ternary alkyl ammonium salts, weak organic acids, or a combination thereof are provided. By including the additives in a crystallization solution with perovskite precursors, larger single crystals can be grown by slow evaporation or inverse temperature crystallization than would possible in the absence of the additives under the same growth conditions.
C30B 7/02 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p.ex. à partir de solutions aqueuses par évaporation du solvant
42.
REFRACTORY ALLOYED IRON-BASED REDOX ACTIVE FOAMS FOR IRON-AIR BATTERIES, FABRICATING METHODS AND APPLICATIONS OF SAME
This invention in one aspect relates to an iron-based foam usable for an electrochemical device, comprising a composition comprising iron and a refractory element processed to form the iron-based foam having a hierarchical porous structure with self-assembled channels for gas flow reactions and internal space to accommodate volumetric changes on oxidation.
B22F 9/04 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par des procédés physiques à partir d'un matériau solide, p.ex. par broyage, meulage ou écrasement à la meule
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
C22C 38/12 - Alliages ferreux, p.ex. aciers alliés contenant du tungstène, du tantale, du molybdène, du vanadium ou du niobium
43.
NEDDYLATION INHIBITION FOR USE IN THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION
Disclosed is a method for the treatment of a subject having an HIV infection or inhibiting neddylation using a neddylation inhibiting enzyme, neural-precursor-cell-expressed developmentally down-regulated 8 (NEDD8)-activating enzyme E1 (NAE1).
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
45.
TARGETING PLECKSTRIN-2 FOR TREATING CANCER AND OTHER DISEASES AND DISORDERS
Disclosed are small molecule inhibitors of Plek2 biological activity. The compositions and method may be utilized for treating cell proliferative diseases and disorders and other diseases and disorders, such as diseases and disorders that are characterized by Plek2 expression and/or by activation of the phosphatidylinositide 3-kinase (PI3K)/Akt pathway. Cell proliferative diseases and disorders that may be treated using the disclosed compositions and methods may include, but not limited to, myeloproliferative neoplasms (MPNs) such as Philadelphia (Ph)-negative MPNs, and cancers such as acute myeloid leukemia (AML) and cancers characterized by solid tumors.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
46.
OHMIC-CONTACT-GATED CARBON NANOTUBE TRANSISTORS, FABRICATING METHODS AND APPLICATIONS OF SAME
One aspect of this invention relates to an ohmic-contact-gated transistor (OCGT), comprising a bottom gate electrode formed on a substrate; a first dielectric layer formed on the bottom gate electrode; a thin film formed of a semiconducting material on the first dielectric layer; a bottom contact formed on a part of the thin film; a second dielectric layer conformally grown on the bottom contact to result in a self-aligned dielectric extension from the bottom contact on the thin film; and a top contact formed on the second dielectric layer on the top of the bottom contact and fully overlapping with the dielectric extension to define a device channel in the thin film under the dielectric extension between the bottom contact and the top contact.
H10K 10/84 - Dispositifs organiques spécialement adaptés au redressement, à l'amplification, à l'oscillation ou à la commutation; Condensateurs ou résistances organiques comportant une barrière de potentiel ou une barrière de surface - Détails de structure Électrodes Électrodes ohmiques, p. ex. électrodes de source ou de drain
H10K 10/46 - Transistors à effet de champ, p. ex. transistors organiques à couche mince [OTFT]
H10K 85/20 - Composés de carbone, p. ex. nanotubes de carbone ou fullerènes
47.
METHODS OF MAKING A LOW-COST MINIATURE ACCOMMODATING OPTICAL IMAGING SYSTEM
Provided herein are methods of making imaging systems. In one aspect, the method may comprise providing a lens; providing an optomechanical assembly; providing an imaging sensor; and operably connecting the optomechanical assembly with said lens and said imaging sensor, forming said imaging system. In some aspects, providing an optomechanical assembly may comprise manufacturing a component of the optomechanical assembly using additive manufacturing. In some aspects, providing an optomechanical assembly may comprise manufacturing a component of the optomechanical assembly using micro-continuous liquid interface production (μCLIP) 3D printing.
Disclosed is minimal essential media for culturing induced human pluripotent stem cells (iPSCs), methods for preparing the media, and methods of using the media.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.”
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
An electrode for a lithium-ion battery includes a substrate; and a composite deposited on the substrate, wherein the composite comprises layered graphene comprising mono-, bi- and n-layered graphene, wherein n is an integer selected from 3-about 6; and nanoparticles of a material selected from a cathode active material and an anode active material, wherein the surface of each of said nanoparticles is coupled to and conformally coated with said layered graphene, and wherein said layered graphene is not graphene oxide and is not reduced graphene oxide.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
H01M 4/131 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p.ex. LiCoOx
H01M 4/133 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de matériau carboné, p.ex. composés d'intercalation du graphite ou CFx
H01M 4/134 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de métaux, de Si ou d'alliages
H01M 4/136 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/1393 - Procédés de fabrication d’électrodes à base de matériau carboné, p.ex. composés au graphite d'intercalation ou CFx
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p.ex. LiMn2O4 ou LiMn2OxFy
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/56 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
C07H 19/00 - Composés contenant un hétérocycle partageant un hétéro-atome du cycle avec un radical saccharide; Nucléosides; Mononucléotides; Leurs anhydro-dérivés
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p.ex. contenant des motifs CpG
52.
ULTRASONIC PRE-SURFACE AND POST-SURFACE PROCESSING FOR LASER BRAZING AND LASER WELDING
A laser brazing and welding system is disclosed and includes: a laser; a first cutting tool including a first cutting tip; and a control module. The control module is configured to control the laser to laser braze or laser weld two parts; and control ultrasonic vibration of the first cutting tip to remove one or more layers from at least one of the two parts prior to or subsequent to the laser brazing or laser welding of the two parts.
An acupressure device includes a mount that is configured to attach to a patient and one or more indenter devices attached to the mount. An indenter device is mounted such that the indenter device is positioned over an acupuncture location of the patient. The indenter device has a base that contacts the mount and a tip that contacts the acupuncture location on the patient.
A61H 39/04 - Dispositifs pour exercer des pressions auxdits endroits, p.ex. shiatsu
A61N 1/18 - Application de courants électriques par électrodes de contact
A61F 13/06 - Bandages ou pansements; Garnitures absorbantes spécialement conçus pour les pieds ou les jambes; Coussinets pour cors; Anneaux pour cors
A61H 11/00 - Ceintures, bandes ou peignes pour massage
A61H 23/00 - Massage par percussion ou vibration, p.ex. en utilisant une vibration ultrasonique; Massage par succion-vibration; Massage avec des membranes mobiles
54.
Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B
Disclosed are methods and compositions for treating cell proliferative diseases and disorders such as cancers. Particularly disclosed are methods and composition for treating cancers such as glioblastoma by administering a therapeutic agent that inhibits the biological activity of the autophagy related 4B cysteine peptidase (ATG4B) protein in conjunction with additional therapeutic agents or treatments.
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p.ex. chlorazanil, mélamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Cortical blood vessel temperature is automatically detected and tracked during an interventional procedure, such as during a neurosurgical procedure. In general, the temperature of blood vessels on the surface of the brain are identified and tracked using data from a brain thermography device, which may include an infrared ("IR") thermal camera. Thermal data are segmented and vessel segments are identified and tracked based on the segmentation. The corresponding temperature measurements for each vessel segment are tracked over the frames of thermal data to track the temperature of blood vessels over time.
An antifouling tile includes a tile blank having a first surface and a second surface opposite the first surface. The antifouling tile also includes a plurality of photocatalytic particles mounted to the first surface of the tile blank. The antifouling tile further includes an ultraviolet (UV) light source mounted to the second surface of the tile blank. The UV light source activates the plurality of photocatalytic particles to prevent biofouling of the tile blank.
B63B 59/04 - Moyens pour éviter la salissure de la coque
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage utilisant des radiations électromagnétiques
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
Disclosed herein are methods and composition for reprocessing crosslinked polyurethanes. The method may comprise mechanically processing the crosslinked polyurethane, mixing the mechanically processed crosslinked polyurethane with a solid polyurethane exchange catalyst, heating the mixture to an effective bond-exchange temperature, and applying mechanical force to the mixture for an effective bond-exchange time. In another aspect the method may comprise heating a polyurethane exchange catalyst and an antioxidant composition, the antioxidant composition comprising the crosslinked polyurethane and an antioxidant, to an effective bond- exchange temperature and applying mechanical force to the polyurethane exchange catalyst and the antioxidant composition for an effective bond-exchange time.
C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
C08G 18/22 - Catalyseurs contenant des composés métalliques
B01J 31/18 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination contenant de l'azote, du phosphore, de l'arsenic ou de l'antimoine
Disclosed are components and methods for RNA-directed DNA cleavage and gene editing. The components include and the methods utilize a Cas9 protein from Neisseria and one or more RNA molecules in order to direct the Cas9 protein to bind to and optionally cleave or nick a target sequence.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/22 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p.ex. Acinetobacter
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
59.
DIAGNOSIS AND TREATMENT OF PRIMARY GRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANT
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
60.
ROOM TEMPERATURE LASING FROM SEMICONDUCTING SINGLE WALLED CARBON NANOTUBES
Optical gain media and gain devices are required for lasing devices and high intensity optical systems across a wide range of application. A compact optical gain device that provides near-infrared and infrared lasing at room temperature includes an optical microcavity having a refractive index and a curvilinear outer surface with an angle of curvature such that the optical microcavity supports the propagation of an electromagnetic whispering gallery mode. A plurality of optical gain structures are disposed along the curvilinear outer surface of the optical microcavity, the each of the optical gain structures having an optically active wavelength range over which each of the corresponding optical gain structures provides optical gain to radiation through stimulated emission.
ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Shah, Nikhil Dipak
Reddy, Narainsai K.
Yamada, Akira
Alias, Basil
Abrégé
A handle assembly for a gouge includes a handle, where a distal end of the handle includes first threads. The handle assembly includes a grip that has an interior channel. At least a portion of the interior channel includes second threads that mate with the first threads on the distal end of the handle to secure the grip to the handle. The handle assembly also includes a collet. A distal end of the collet includes an opening that is sized to receive a proximal end of a gouge. The handle assembly further includes a collar that is sized to receive the collet, and that mounts onto a distal end of the grip.
One aspect of this invention relates to synthesis of borophane polymorphs by hydrogenating borophene with atomic hydrogen in ultrahigh vacuum, including growing borophene on a substrate in an ultrahigh vacuum chamber; and performing hydrogenation of the borophene in situ to obtain borophane having a diverse set of borophane polymorphs. The borophane polymorphs are metallic with modified local work functions that can be reversibly returned to pristine borophene via thermal desorption of hydrogen. Hydrogenation also provides chemical passivation such that the borophane polymorphs have negligible oxidation for multiple days following ambient exposure.
The present invention provides bispecific antibodies that target T cells to melanoma cells. The bispecific antibodies comprise a first single-chain variable fragment (scFv) that binds to the T cell co-receptor CD3ε and a second scFv that binds to the melanoma marker protein tyrosinase- related protein 1 (TYRP1). Methods of using the bispecific antibodies to treat tumors and lyse target cells are also provided.
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
64.
PI3K INHIBITORS FOR PROTECTION AGAINST GLUCOCORTICOID-INDUCED ATROPHY
Provided herein are methods of treating and preventing steroid-induced atrophy (e.g., skin atrophy, osteoporosis, etc.) by the administration of PI3K/Akt/mTOR inhibitors and pharmaceutical compositions and combinations therefor.
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes contenant des hétérocycles, p.ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p.ex. oxandrolone, bufaline
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone substitués en position 21, p.ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget de l'ostéoporose
Esophageal bolus transport and esophageal mechanics are quantified from medical imaging data, such as dynamic magnetic resonance imaging (“MRI”) data, computed tomography (“CT”) data, or the like. A machine learning model is used to process geometric or other spatiotemporal parameters of a bolus imaged with medical imaging in order to estimate quantitative parameters of the bolus and/or esophagus, such as cross-sectional area, fluid velocity, and fluid pressure. From these values, other parameters can be computed, such as esophageal stiffness and active relaxation.
In one aspect, this invention relates to a bioactive implant comprising an electrode array; and a source of neurotrophins coupled with the electrode array for generating a neurotrophin concentration gradient that facilitates a neuro-regenerative nexus (NRN) for survival, neuronal differentiation toward spiral ganglion neurons (SGNs), and directed neurite extension of human pluripotent stem cell (hPSC)-derived SGNs. The invention in another aspect also relates to a method for realization of the NRN in conjunction with an implant, comprising coupling a source of neurotrophins with the electrode array to generate a neurotrophin concentration gradient that facilitates the NRN for survival, neuronal differentiation toward SGNs, and directed neurite extension of hPSC-derived SGNs.
The invention relates to a sterilizable and reusable ultraviolet-resistant elastomer composites including an elastomeric matrix comprising at least one elastomer; and an UV-resistant additive incorporated into the elastomeric matrix. The ultraviolet-resistant elastomer composite remains mechanically robust over at least 150 sterilization cycles, enabling safe reuse following ultraviolet germicidal irradiation (UVGI). Beyond N95 masks, these UVGI-compatible ultraviolet-resistant elastomer composites have potential utility in other PPE applications to address the broader issue of single-use waste.
The present disclosure describes systems and methods to evaluate auditory efferent function by exposing a patient to short-duration acoustic click stimuli to generate a click-evoked otoacoustic emission (CEOAE) occurring in each ear of the patient, and in response to exposing the patient to click stimuli, concurrently sampling outer hair cell activity (OHC) and medial olivocochlear reflex (MOCR; efferents) in each ear of the patient, monitoring the middle ear muscle reflex (MEMR) in each ear of the patient, and measuring a change in cochlear activity in the patient based on the CEOAE, MOOR, and MEMR of each ear of the patient.
ANN AND ROBERT H. LURIE CHILDREN’S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Rogers, John A.
Lu, Wei
Forbess, Joseph M.
Ge, Zhi-Dong
Abrégé
The invention relates to an optoelectronic system. The optoelectronic system includes an optoelectronic probe operably attached to a target region of a subject; and an electronic module coupled with the optoelectronic probe for wireless, real-time, and continuous measurements of physiological information of the subj ect.
A61B 5/1459 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale invasifs, p.ex. introduits dans le corps par un cathéter
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
A61B 5/0215 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par des moyens introduits dans le corps
A continuous bedside pressure monitoring (CBPM) device includes an array of pressure sensors, a controller including a processor and a memory, the controller operatively coupled to the array of pressure sensors, a communication interface operatively coupled to the controller, and a flexible housing enclosing the array of pressure sensors, the controller, and the communication interface.
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A catheter-based baro-hydrometer device measures or otherwise monitors esophageal function. The device includes a segmented balloon design, including a first and second balloon whose fill volumes can be independently controlled. In general, the device leverages secondary peristalsis related to balloon distention in order to study esophageal function. Pressure sensors coupled to the balloons record pressure data, which can be classified and processed to measure or otherwise monitor esophageal function.
Provided are circuits for integrating image processing into image sensors. Multiple configurations of sensors are described which generate specific motion and shape-based responses to changes in received light intensity. These sensor configurations may be used to pre-process images and to provide additional context to light intensity data. The sensor configurations may include memory circuits and signal conditioning.
An artificial intelligence (AI)-based knowledge distillation and paper production computing system processes instructions to use machine learning models to automatically review papers from a large corpus of papers and distill knowledge using science of science methods and AI-based modeling techniques. The AI-based knowledge distillation and paper production computing system processes instructions to leverage network science and machine learning tools to analyze papers with respect to a given topic to find relevant scientific publications, organize and group publications based on topic similarity and relation to the topic in general, and distill and summarize the message and content of these publications into a coherent set of statements.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
NORTHWESTERN UNIVERSITY (USA)
Inventeur(s)
Frankowski, Kevin
Wang, Feijun
Huang, Sui
Freeman, Emma
Abrégé
The current invention relates to transcription elongation factor eEFlA2-targeted protein degradation ligands and pharmaceutical compositions thereof and their utility as anti-cancer agents.
Disclosed are substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs). The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC. The disclosed PROTACs are shown to induce degradation of c-MYC protein. The substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs) disclosed, herein may be utilized as therapeutics for treating cancer and cell proliferative disorders.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
The present disclosure relates generally to an enzyme building block for the assembly of megamolecules. The system is based on the inhibition of the human-derived cellular retinoic acid binding protein II (CRABP2) domain. The inventors synthesized a synthetic retinoid bearing an arylfluorosulfate group, which uses sulfur fluoride exchange click chemistry to covalently inhibit CRABP2. The inventors conjugated both the inhibitor and a fluorescein tag to an oligo( ethylene glycol) backbone and measured a second-order rate constant for the protein inhibition reaction of approximately 3,600 M-1s-1. The inventors used this new enzyme-inhibitor pair to assemble multi-protein structures in one-pot reactions using three orthogonal assembly chemistries to demonstrate exact control over the placement of protein domains within a single, homogeneous molecule. This work enables a new dimension of control over specificity, orientation, and stoichiometry of protein domains within atomically precise nanostructures.
79.
HYDRATION SENSORS FOR MONITORING AND DIAGNOSIS OF SKIN DISEASES IN ANY ENVIRONMENT
This invention relates to a soft, battery-free, flexible, non-invasive, reusable hydration sensor adherable to even small-areas and curvilinear surfaces of a body. The hydration sensor measures volumetric water content in skin as a function of depth, and wirelessly transmits data to a portable smart device. The hydration sensor includes a top layer for thermal, chemical and mechanical isolation of the hydration sensor from an environment; a bottom layer operably placed on a target area of interest on the skin; and a flexible printed circuit board (f-PCB) disposed between the top layer and the bottom layer. The f-PCB contains electronics for sensing and wireless communication. The bottom layer operably serves as a direct interface between the f-PCB and the skin and comprises a flexible adhesive for attaching the hydration sensor to the skin.
Systems and methods that enable automated spray deposition of biological specimens carried on microscope slides are described herein. Aspects of the technology are directed, for example, to automated specimen deposition systems and methods of generating high-quality, reproducible specimen-bearing microscope slides in automated processing systems.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
G01N 1/28 - Préparation d'échantillons pour l'analyse
81.
METHOD AND SYSTEM FOR USING FITTED RELAXATION DATA TO IMPROVE A PRODUCT
A system to improve a product based on a relaxation response includes a memory configured to store relaxation response data of a sample. The relaxation response data includes time data and amplitude data. A processor is operatively coupled to the memory and configured to convert the relaxation response data to linear-amplitude versus log-time data. The processor also performs a least-squares fit of the converted relaxation response data to a heavy-tail function to determine one or more fit parameter values. The processor also updates a design for the sample based at least in part on the one or more fit parameter values.
G01R 33/44 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance magnétique nucléaire [RMN]
82.
MATERIALS AND METHODS FOR MODIFYING EXPRESSION OF MYOSIN HEAVY CHAIN GENES
Described herein is a method for editing the MHY7 gene in a cell by genome editing comprising introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more double stranded breaks (DSBs) within or near enhancer regions of the MYH7 gene or MYH6 gene that results in deletion of one or more enhancer regions of the MYH7 gene.
Disclosed are methods, systems, components, and compositions for cell-free synthesis of proteins and glycoproteins. The methods, systems, components, and compositions may be utilized for incorporating non-standard amino acids (nsAAs) into cell-free synthesized proteins and glycosylating or otherwise modifying the cell-free synthesized proteins in vitro. The nsAAs of the cell-free synthesized protein may be modified via glycosylation or other modification.
The present teachings provide methods for providing populations of single-walled carbon nanotubes that are substantially monodisperse in terms of diameter, electronic type, and/or chirality. Also provided are single-walled carbon nanotube populations provided thereby and articles of manufacture including such populations.
A method of making colloidal crystals using seed programmable atom equivalents (PAEs) and growth programmable atom equivalents (PAEs) for at least two stage growth. The seed and growth PAEs each include nanoparticles functionalized with oligonucleotides with sticky ends. Seed PAEs have sticky ends adapted to hybridize to each other to form a first duplex, and growth PAEs have sticky ends adapted to hybridize to a respective ones of the seed PAEs and to each other to form second, third, and fourth duplexes. Using base mismatches in the sticky ends of the growth PAEs and a two stage cooling, the first duplex having a higher melting temperature than the other duplexes nucleate the seed PAEs as seeds in a first stage and remaining duplexes form in a second lower temperature stage for growth on the seeds.
B01J 13/00 - Chimie des colloïdes, p.ex. production de substances colloïdales ou de leurs solutions, non prévue ailleurs; Fabrication de microcapsules ou de microbilles
The present technology relates to cell-free systems, methods, and kits for expressing proteins in vitro and evaluating the expressed proteins. In particular, the technology relates to cell-free systems, methods, and kits for expressing antibodies, antigen-binding fragment thereof, and antibody derivatives in vitro and evaluating the expressed antibodies, antigen-binding fragment thereof, and antibody derivatives.
G01N 33/535 - Production de composés immunochimiques marqués avec un marqueur enzymatique
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
Provided herein are devices that facilitate the magnetic separation of an analyte from a sample, and methods of use thereof. In particular embodiments, devices and methods are provided for the trans-interfacial magnetic separation (TIMS) of analytes from a sample.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
B01L 7/00 - Appareils de chauffage ou de refroidissement; Dispositifs d'isolation thermique
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
Provided herein are balloon delivery systems (BDSs) for deploying expandable implants at treatment locations within a subject. In particular provided herein are BDSs providing optimal deployment of bioresorbable vascular scaffolds (BVS), for example, within a coronary artery.
A61F 2/958 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes ballons gonflables pour insérer les stents ou les endoprothèses déployables couvertes
A61F 2/01 - Filtres implantables dans les vaisseaux sanguins
A61F 2/966 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes possédant une gaine extérieure avec un mouvement longitudinal relatif entre la gaine extérieure et la prothèse, p.ex. utilisant une tige poussoir
A61F 2/86 - Stents ayant une forme caractérisée par des éléments filiformes; Stents ayant une forme caractérisée par une structure de type filet ou de type à mailles
90.
POLAR ETHYLENE-BASED POLYMER WITH REVERSIBLE CROSSLINKER
The present disclosure provides a crosslinkable polymer composition. In an embodiment, the crosslinkable polymer composition includes a polar ethylene-based polymer, a free radical initiator, and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate). The present disclosure provides a crosslinked composition. In an embodiment, the crosslinked composition includes a polar ethylene-based polymer; and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate).
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide that (i) inhibits aggregation of, (ii) accelerates aggregation of, (iii) binds to, and/or (iv) mimics: (a) at least a portion of Tau protein, and/or (b) at least a portion of microtubulin protein.
Disclosed herein are single crystal imine-linked 2D-covalent organic frameworks (COFs), methods of making and using the same. In some embodiments, the imine-linked 2D-covalent organic frameworks are used to separate a mixture.
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/281 - Absorbants ou adsorbants spécialement adaptés pour la chromatographie préparative, analytique ou de recherche
Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/24 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p.ex. cyclométhicone ou phospholipides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
94.
ENGINEERED HYPOXIA BIOSENSORS AND METHODS OF USING THE SAME
The present disclosure relates generally to hypoxia biosensors. In particular, the present disclosure relates to hypoxia biosensors that employ engineered genetic circuits for enhanced biosensor sensitivity and response. Some engineered genetic circuits employ positive feedback and amplification of expression in order to promote high-efficiency reporting of hypoxia.
The present disclosure provides a crosslinkable polymer composition. In an embodiment, the crosslinkable polymer composition includes an ethylene-based polymer, a free radical initiator, and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate). The present disclosure provides a crosslinked composition. In an embodiment, the crosslinked composition includes an ethylene-based polymer; and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate).
Provided herein are devices for prolonged securement of medical devices to a subject. In particular, drain tubes (e.g., percutaneous drains), catheters, and other medical devices are secured near the insertion site using the devices herein.
Provided herein are devices for sutureless securement of medical devices to a subject. In particular, drain tubes (e.g., percutaneous drains), catheters, and other medical devices are secured to the skin of a patient (e.g., near the insertion site) using the devices herein.
A process to form a composition comprising an ethylene/vinylarene multiblock interpolymer, said process comprising polymerizing, in a single reactor, a mixture comprising ethylene, a vinylarene, and optionally an alpha-olefin, in the presence of at least the following a)-c): a) a first metal complex selected from the following Formula (A), as described herein: b) a second metal complex selected from the following Formula (B), as described herein, and c) a chain shuttling agent selected from the following: a dialkyl zinc, a trialkyl aluminum, or a combination thereof. A composition comprising an ethylene/vinylarene multiblock interpolymer comprising at least one polymer structure selected from: -(AR)-(AP)-(AR)-(AP)- (Structure 1), or (AR)-(AP)-(AR)-(AP) (Structure 2); where each (AR) segment independently comprises, in polymerized form, ethylene, >10 mol % of the vinylarene and optionally an alpha-olefin, and wherein each (AP) segment independently comprises, ethylene, optionally ≤10 mol % vinylarene and optionally the alpha-olefin.
A process to form a composition comprising an ethylene/vinylarene multiblock interpolymer, said process comprising polymerizing, in a single reactor, a mixture comprising ethylene, a vinylarene, and optionally an alpha-olefin, in the presence of at least the following a)-c): a) a first metal complex selected from the following Formula (A), as described herein: b) a second metal complex selected from the following Formula (B), as described herein, and c) a chain shuttling agent selected from the following: a dialkyl zinc, a trialkyl aluminum, or a combination thereof. A composition comprising an ethylene/vinylarene multiblock interpolymer comprising at least one polymer structure selected from: -(AR)-(AP)-(AR)-(AP)- (Structure 1), or (AR)-(AP)-(AR)-(AP) (Structure 2); where each (AR) segment independently comprises, in polymerized form, ethylene, >10 mol % of the vinylarene and optionally an alpha-olefin, and wherein each (AP) segment independently comprises, ethylene, optionally ≤10 mol % vinylarene and optionally the alpha-olefin.
C08F 297/08 - Composés macromoléculaires obtenus en polymérisant successivement des systèmes différents de monomère utilisant un catalyseur de type ionique ou du type de coordination sans désactivation du polymère intermédiaire utilisant un catalyseur du type de coordination en polymérisant des mono-oléfines
99.
ROBOTIC END EFFECTOR SYSTEM AND METHOD WITH LOCKABLE COMPLIANCE
Robotic systems and methods are provided with an end effector having lockable compliance. A robotic system for manipulating a workpiece includes an arm having a pair of sections connected by a joint assembly, with a lock disposed in the joint assembly. A gripper is connected on the arm and is configured to alternately grip and release the workpiece. A controller operates the lock to alternately lock and unlock the joint assembly. The gripper holds the workpiece during a deformation of the workpiece, while the controller may unlock the lock to allow movement of the joint assembly to relieve forces on the arm arising during a deformation of the workpiece.
